Should Preteens Get One or Two HPV Shots?
U.S. health officials and medical groups are debating whether preteens need one or two doses of the HPV vaccine. Recent studies suggest a single shot may offer protection similar to two, but the federal government has stalled changes. The debate highlights vaccine policy tensions and the need for c…
By Felo News Desk · Published
Preteens across the United States may soon face a decision that could change the way they protect themselves against a common sexually transmitted infection and the cancers it can cause. For the first time in a decade, experts are seriously considering whether a single dose of the human papillomavirus (HPV) vaccine might provide the same level of protection as the current two‑dose schedule.
What Is HPV and Why Is the Vaccine Important?
Human papillomavirus is the most common sexually transmitted infection in the U.S., with over 40 strains that can infect the genital area, mouth, and throat. While many infections resolve on their own, certain high‑risk strains are responsible for nearly 90% of cervical cancer cases and a large share of anal, head‑and‑neck, and other cancers. The HPV vaccine, first approved in 2006, targets the most dangerous strains and has been shown to reduce infections, genital warts, and precancerous lesions worldwide.
How the Vaccine Schedule Has Evolved
When the vaccine was first introduced, it was recommended as a three‑dose series for girls and later expanded to boys in 2011. In 2011 the U.S. Centers for Disease Control and Prevention (CDC) shifted the target age to 11‑12 years, emphasizing that protection is strongest before sexual activity begins. A decade later, research demonstrated that two doses spaced 6–12 months apart were as effective as three, and the schedule was updated accordingly. Today, the standard recommendation is two doses for most adolescents, with a single dose for those 15 or older.
New Evidence Suggests One Dose May Be Enough for Girls
In late 2023, a large Costa Rican study followed more than 20,000 girls for five years and found that a single HPV shot provided about 97% protection against cervical cancer—essentially the same efficacy as two doses. The study’s findings have sparked renewed interest among researchers and public health officials. In 2024, the CDC’s Advisory Committee on Immunization Practices (ACIP) formed a working group to examine the possibility of revising the recommendation, but the group’s work was halted when the newly appointed U.S. Health Secretary, Robert F. Kennedy Jr., dismissed its members.
Meanwhile, the American Academy of Pediatrics (AAP), which had previously sued Kennedy over his interference, is also reviewing its own guidance. AAP officials, including Dr. James Campbell, chair of the infectious diseases committee, have expressed openness to exploring a one‑dose schedule for certain age groups while noting that evidence for males and for broader protection remains limited.
Federal Disputes and Legal Challenges
In January 2024, Secretary Kennedy unilaterally ordered a reduction of the recommended HPV doses to one for all preteens. A federal judge quickly issued an injunction blocking the change, citing the need for a data‑driven approach. The move has intensified tensions between the federal government and medical societies, which argue that any shift must be based on robust evidence and clear communication to avoid public confusion.
Legal battles have also involved the AAP, which filed a lawsuit against Kennedy’s decision. The case underscores a broader struggle over vaccine policy, with some groups advocating for streamlined schedules to improve uptake and others cautioning against premature changes that could undermine confidence.
Current Vaccination Rates and Public Perception
Despite the vaccine’s proven benefits, CDC data show that only about 63% of teenagers receive both recommended doses, a figure that has plateaued for four years. State requirements for school entry vary, and many parents report concerns about pain—HPV shots are known to sting more than some other adolescent vaccines—and the risk of fainting. Dr. Scott Hadland, a pediatrician in Boston, notes that while the discomfort is brief, it can deter some families from completing the series.
Public trust has also been challenged by misinformation. Kennedy’s past legal work against Merck, the manufacturer of Gardasil, and his public statements claiming the vaccine increases cancer risk have fueled skepticism among certain groups.
What’s Next for HPV Vaccine Recommendations?
As the debate continues, experts emphasize that the most reliable guidance remains the two‑dose schedule for adolescents aged 11–14, with a single dose for those 15 and older. The AAP and other professional societies are awaiting the results of ongoing studies and the outcome of the legal disputes before making definitive changes. In the meantime, public health officials urge parents to follow current recommendations and to discuss any concerns with their healthcare provider.
Ultimately, the conversation around HPV vaccination reflects broader questions about how quickly medical guidelines should evolve in response to new data and how to balance innovation with public confidence. The outcome will shape not only individual health decisions but also the trajectory of HPV‑related disease prevention in the United States.
Key facts
- HPV causes nearly 50,000 U.S. cancers yearly and is the most common STI.
- The standard schedule is two doses for 11‑14‑year‑olds, one dose for 15+.”
- A Costa Rican study suggests one dose may protect girls as well as two.
- Federal disputes and legal challenges have stalled any official change.”
- Vaccination rates remain flat at 63% for both doses.”
Why it matters
The potential shift to a single‑dose HPV schedule could simplify vaccination, improve coverage, and reduce costs, but it also risks public confusion and undermines trust if not grounded in solid evidence.
Frequently asked questions
Can a single HPV shot protect against all HPV‑related cancers?
Current evidence shows a single dose offers strong protection against cervical cancer in girls, but data for other cancers and for boys are less conclusive.
Will the CDC change its recommendation soon?
The CDC’s advisory committee is still reviewing the evidence, and any change will require a formal recommendation process.
Is the HPV vaccine safe?
Extensive studies have shown the vaccine to be safe, with common side effects including mild pain and rare fainting episodes.
